BioPharmSignal logoBioPharmSignal

Biotech News

Jaguar Health Reports Approval of All Proposals at 2026 Annual Meeting of Stockholders

Jaguar Health (JAGX)Jaguar HealthFDA / regulatory

Lisa Conte, Jaguar's founder, president & CEO, presenting virtually on June 10, 2026 at the Emerging Growth Conference; click here to register SAN FRANCISCO, CA / ACCESS Newswire / June 8, 2026 / Jaguar Health, Inc. ( NASDAQ:JAGX) ("Jaguar" or the "Company") today announced the voting results of

Related news

JAGXJaguar Health2026-04-20 20:15 EST

Jaguar Health Reports Approval of All Proposals at April 2026 Special Meeting of Stockholders

JAGXJaguar Health2026-06-23 13:00 EST

Jaguar Health Completes Submission of New Animal Drug Application for Full FDA Approval of Crofelemer for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs

IBRXImmunityBio2026-03-20 17:08 EST

ImmunityBio Announces Approval in Macau SAR, China for ANKTIVA® in BCG-Unresponsive NMIBC with CIS ± Papillary Tumors

HROWHarrow, Inc.2026-08-06 11:00 EST

Harrow Acquires Global Rights to TYRVAYA®, the First and Only FDA-Approved Nasal Spray for Dry Eye Disease

IBRXImmunityBio2026-05-20 00:30 EST

ImmunityBio Announces FDA Acceptance of Supplemental BLA for ANKTIVA® Plus BCG in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer with Papillary Disease; PDUFA Date Set for January 6, 2027

HROWHarrow, Inc.2026-02-17 12:00 EST

Harrow Announces Cash-Pay Direct-to-Prescriber PharmaPack™ Kits

SCYXSCYNEXIS2026-01-21 13:00 EST

SCYNEXIS Receives FDA Qualified Infectious Disease Product (QIDP) and Fast Track Designations for SCY-247

SCYXSCYNEXIS2026-01-28 13:00 EST

SCYNEXIS Announces Presentations Highlighting the Potent Antifungal Activity of its Second-Generation Fungerp, SCY-247 Against Drug-Resistant Fungi, at the Inaugural Interdisciplinary Meeting on Antimicrobial Resistance and Innovation (IMARI)

View all latest news

Jaguar Health

Jaguar Health is a biopharmaceutical company focused on gastrointestinal and rare-disease therapies, with Mytesi as a key commercial asset. Its story combines niche commercialization with a pipeline aimed at high-unmet-need GI indications.

Recent company news

JAGXJaguar Health2026-08-19 20:00 EST

Jaguar Health Reports Second Quarter 2026 Financials

JAGXJaguar Health2026-08-18 13:00 EST

Jaguar Health to Hold Investor Webcast August 19 Regarding Q2 2026 Financials & Corporate Updates

JAGXJaguar Health2026-08-05 13:00 EST

Jaguar Health Satisfies Conditions for Receipt of Non-Dilutive $2 Million Holdback Payment from Future Pak for Commercial License to Mytesi and Canalevia-CA1

JAGXJaguar Health2026-07-28 13:00 EST

Jaguar Health Reports Positive Consumer and Veterinary Market Research Findings Supporting Commercial Opportunity for Neonorm Dog

JAGXJaguar Health2026-07-22 13:00 EST

Additional Infant Patient to Receive Jaguar Health's Crofelemer for Compassionate Use for Treatment of Intestinal Failure (IF) Due to Microvillus Inclusion Disease (MVID)

Stock data

Close
0.87 USD
Market cap
2.12M USD
Exchange
NASDAQ
Sector
Biopharma
Location
San Francisco, California